Open AccessRole of pre-biopsy multiparametric MRI in prostate cancer diagnosis: Evidence from the literature
Author(s) -
David Leung,
Peter KaFung Chiu,
ChiFai Ng,
Jeremy YuenChun Teoh
Publication year - 2021
Publication title -
turkish journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.347
H-Index - 8
eISSN - 2149-3057
pISSN - 2149-3235
DOI - 10.5152/tud.2020.20360
Subject(s) - prostate cancer , multiparametric mri , medicine , biopsy , radiology , cancer , pathology
As the conventional workup for diagnosing prostate cancer, transrectal systematic biopsy carries the risk of sepsis and overdiagnosis of insignificant prostate cancer. In recent years, multiparametric MRI (mpMRI) has revolutionized the diagnostic approach to prostate cancer. With widespread use of the prostate imaging and data system (PIRADS), MRI reporting has been more standardized. Several landmark papers have indicated that mpMRI in combination with targeted or combined biopsy can confidently diagnose more clinically significant prostate cancer while reducing diagnoses of insignificant disease. In this review, we aim to discuss the advantages of pre-biopsy MRI based on the current literature and to address its reliability in ruling out prostate cancer, reproducibility, and cost-effectiveness.